← All trials
NCT05170568
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Dec 1, 2022
- Completion date
- Dec 1, 2024
- First posted
- Dec 28, 2021
- Last posted
- Nov 1, 2022
- Enrollment
- 22
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Peking UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- Zhengzhou UniversityCollaborator
- Zhengzhou UniversityOverall official - principal investigator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.